Which sectors in EM will benefit most from the coronavirus outbreak?

Our EM equities team has been speaking with contacts on the ground in China and across Asia to understand how the coronavirus is changing behavior and industries.

04 Mar 2020

Key highlights: Coronavirus and emerging markets: on-the-ground views

  • The coronavirus outbreak will have a clear short-term economic impact on both China and economies throughout the Asia region;
  • The extent and duration of the impact will depend on containing the spread in Asia and around the world, as well as the extent of policy support. China, Singapore and Hong Kong are already rolling out support measures;
  • Global markets have only recently reacted negatively and could remain volatile in the near term; however, the long-term impact should be negligible, especially judging by previous cases such as MERS and SARS;
  • In China, the outbreak is accelerating a series of trends, including:

Ongoing industry consolidation: many smaller firms are finding it difficult to cope and will likely go out of business. Stronger and larger players are likely to benefit by growing market share.

An offline-to-online shift across business segments: more pronounced in industries such as after-school tutoring, banking, and healthcare diagnosis; offline-only businesses are likely to lose market share;

Investment in R&D and innovation: driven by growing demand for automated solutions, AI-driven technology, high-quality healthcare, as well as online entertainment and communication services;

Supply chain shifts: coronavirus provides additional impetus to diversify, and favored destinations are South-East Asia and India and reshoring, especially to North America, South Korea or Japan.

  • We remain confident in fundamental, long-term changes playing out in emerging markets and our strategies are focused on quality companies associated with them.
  • Despite market resilience in the wake of the coronavirus outbreak, we remained cautious, preferring to hold some risk budget in case opportunities emerged. We remain cautious but now, as markets digest the situation, we are prepared to make portfolio changes at appropriate price points, especially by adding to positions in high-quality industry leaders.

Short-term impact significant, but stimulus measures are in the pipeline

The short-term impact of coronavirus on China's economy could be significant, largely because of the considerable precautions taken, like travel restrictions and factory closures.

However, the growth rate of new cases has slowed markedly in China while picking up pace elsewhere in the world.

China: new coronavirus cases, Jan 22nd, 2020-February 27th, 2020

Source: Johns Hopkins CSSE, February 28,2020

In China, many large companies and state-owned enterprises have resumed work, but smaller companies face more of a struggle. Depending on the sector and progression of the situation, it is estimated that the impact of work disruptions could last for one to two quarters.

Government efforts to support China's economy have been considerable, including cuts to interest rates, cuts to selected banks' required reserve holdings (RRR), support for small-and-medium enterprises, and relaxation of home purchase restrictions in some parts of China.

In Asia, there will likely be spillover effects, with the heaviest impact on countries dependent on tourism, commodity exports and trade flows.

Taking Asian tourism as an example, Chinese tourists account for a large portion of tourist spending. In Thailand, tourist spending accounts for about 12% of GDP, and approximately 28% comes from Chinese tourists. Other Asian countries significantly exposed to Chinese tourism include Hong Kong, Singapore, and Malaysia.

However, we are beginning to see support measures across the region, including stimulus measures in Singapore and Hong Kong, infrastructure spending in China. Furthermore, there is a rising likelihood of further interest rate cuts.

FY2020: GDP Forecasts Across Asia: Old vs New

Source: UBS, December 20, 2019 & February 28, 2020

Supply chain restoration underway; companies are relocating out of China, but they are not rushing

In the shorter term, many industries across the world with parts of their supply chain linked to China will likely face supply constraints in Q1 and possibly Q2. The rest of Asia also has significant supply chain exposure to China.
On average, China accounts for 20% of imports in the rest of Asia. But the restoration of supply is now underway. For example, logistics companies who were operating at 15% capacity at the trough are now at about 80% capacity.
Large companies and SOEs  have much higher work resumption rates, while small companies face more of a struggle. Coal mining, steel, food manufacturing have seen a faster pace of work resumption.
Restoration is slower in the auto sector, which is currently estimated to be at 30% capacity due partly to low expected demand.
Overall, the shorter term impact seems to be on the mend in China and by extension the rest of Asia, though there are downside risks with the virus now going global.

Even prior to Covid-19, the move to reduce dependence on the China supply chain had started, driven by rising costs in China and rising automation reducing labor cost differentials, the trade conflict and tariffs, and a general desire to diversify China risk. Covid-19 provides an additional impetus to diversify from the China supply chain

This diversification is widespread across industries, but is a slow process. Many companies are looking at a China plus one strategy, hence China will continue to be an important production base for companies.

Favored destinations are South-East Asia (with Vietnam the top destination), India and reshoring to North America, Korea or Japan.

Restructuring the supply chain is often accompanied by automation, benefitting factory automation companies. Selected companies in South-East Asia and India should also benefit, but the impact is more diffuse.

Impact of coronavirus across sectors in emerging markets

China's consumer sector will see a near-term growth slowdown, but the extent of the impact and the time of recovery will vary by each consumer sub-segment.

Enforced closures mean sub-sectors like restaurants, sportswear and spirits & beer are most exposed to the slowdown.

For example, Yum China announced that it had closed 30% of its restaurants in China and other chains like Xiabu Xiabu and Haidilao have also announced temporary closures.

Additionally, China's auto sector will likely see a significant drop in sales and production in the near-term: we're currently seeing 30%-50% utilization across the supply chain, and only 20%-30% of dealerships open in mainland.

It is highly likely that China's government will apply support policies, potentially in the form of cuts to purchase taxes, continued subsidies for electric vehicles, and increased license quotas.

Aside from hoarding of essential items, supermarkets and consumer staple sectors aren't likely to see meaningful long-term impact. Retailers with O2O (offline/online to online/offline) support will be less impacted than pure offline players.

Online after-school tutoring companies are seeing a surge in demand amid closures of offline classes1, and we see this as an opportunity for leading online companies in the sector to take market share.

Leaders in the restaurant sector may benefit if, as we expect, smaller players are forced out of the market. Larger players can exploit the situation by securing good locations with favorable rental terms.

Organized and established players may also benefit in the long term if consumers put more emphasis on hygiene and health considerations when selecting restaurants. For the same reason, the food manufacturing sector may also see consolidation.

We expect more emphasis within China on sport and exercise since coronavirus has hit those already in poor health especially hard. Given high entry barriers, China's leading sports apparel companies, including Nike, Adidas, Li Ning and Anta, may see stronger sales coming from a heightened focus on staying healthy.

1Source: Marketwatch, February 2020

Online travel and on-demand food delivery have been adversely affected by travel & work restrictions in China as well as a shift toward home-dining and self-cooking amid restaurant closures and hygiene concerns.

The impact on e-commerce and online advertising in China has been relatively neutral.

For e-commerce, reduced sales of apparel and home appliances have been balanced by increased sales of health products and groceries. For online advertisers, ad spending from online games and education companies has been strong, but other advertisers have canceled their marketing budgets.

Virtual economy subsectors have benefited the most.

Take online gaming for example, user traffic grew between 30% and 50% during the Chinese New Year period. Social video providers like iQiyi, Bilibili, TikTok, and Kuaishou have seen increases in daily time spent, and online diagnosis services like Alihealth, Alibaba's online healthcare platform, and DXY (Ding xiang yuan), an online healthcare community site, have seen significant increases in demand.

Finally, software-as-a-service (SAAS) companies have seen a notable shift in demand. The most downloaded apps in Apple's China iOS store include work communication apps like DingTalk (owned by Alibaba), Zoom, and Enterprise Weixin (owned by Tencent).

Dingtalk has seen daily average users exceed 100 million, with total registered users growing to 300 million. Crucially, Dingtalk has penetrated government, educational and medical institutions, which could mean strong potential for further monetization.

In the short-term, patients are avoiding hospital visits which may adversely impact sales of treatments or drugs that have to be administered in hospitals.

At the industry level, the surge in cases highlighted vulnerabilities within China's primary healthcare institutions. As a remedy, we expect a concerted effort by the government to improve health services, which will likely boost demand for companies operating in the following areas:

Testing equipment: such as polymerase chain reaction (PCR) testing and computerized tomography (CT) tools for lung imaging. China's National Medical Products Administration (NPMA) approved seven rapid-testing kits in late-January.

Treatment: including development of anti-viral drugs, improvement of blood plasma self-sufficiency, and establishment of critical care medicine and intensive care units (ICU). Demand is high for devices and materials to enhance basic ICU infrastructure, like defibrillators, ECGs, blood purifiers, and biochemistry analyzers. Most of these devices are imported and we believe that domestic players will strengthen product innovation and design capabilities to meet higher demand.

Diagnosis: hospitals using a multi-department team (MDT) model that relied on cooperation between different departments were able to reduce the severity rate of the coronavirus cases in mainland China. We believe this would likely become a trend or working practice, which could boost investment in technologies that promote cooperation across regions.

Preventative solutions: such as high-quality vaccines.

The biggest short-term impact from coronavirus will be on business segments driven by face-to-face interaction, like insurance and wealth management. This is especially so in China and the most affected parts of certain Asian cities. 

In China, movement restrictions and the shut down of commercial activities have hurt loan demand. Asset quality pressure is growing amid weaker cashflow, but this is being offset to some degree by government efforts to boost liquidity and bank steps to relax payment terms.

In the rest of Asia, so far the impact of coronavirus has been minimal because official responses have been less draconian and the disease has spread more slowly compared to China. However, the virus is gradually affecting economic activity through reduced tourism, social gatherings and delayed supply chains.

We expect government support measures, including liquidity support for small-and-medium enterprises, cash handouts, and relaxed recognition of non-performing loans to ensure lending lines continue. A slower business environment is expected in 1H20, but most companies predict a fast rebound in 2H20 if the spread of the virus abates.

The virus outbreak will accelerate the push into digital banking, as well as increase scrutiny on banks' digital capabilities. Those having done the best job are in line to benefit.

In China's online lending industry, loan volumes are down significantly y-o-y, partly due to lower demand but also due to lenders' tighter policies, which have lowered approval rates and favored only existing borrowers.

Management are seeing asset quality pressure and higher delinquencies are likely. Currently, loan collection teams have returned to 80% of the normal capacity.

Banks and financial institutions are hungry for high-quality assets as they are required to provide more lending but there is a lack of high-quality borrowers in the market. The large online lending platforms, acting as the loan facilitator, may be a potential source of assets for them.

End demand will slow in the short-term. On the supply-side, companies will likely have to with falling end demand, securing sufficient upstream components; managing the return and safety of workers coming back into the production line for those with manufacturing facilities in China

Looking longer-term, this current crisis may lead to greater demand for devices that facilitate offsite work and interaction. Such devices require better connectivity, mobility, bandwidth and so on, so greater investment in in networks and datacenters is likely.

On the supply side, this crisis may highlight the risk of concentrating production in one country or region and may accelerate the relocation of some manufacturing facilities away from China. Investment in automation may also pick up pace.

China's government will pressure utility companies to cut prices and power plants (coal-fired and nuclear) and sewage treatment companies will be most impacted. Gas distributors enjoy a degree of pricing power due to their quasi-monopoly status and should be less affected.

Within industrials, subsectors exposed to long and complicated supply chains are most exposed such as auto glass providers and construction companies.

However, automation and surveillance companies may be long-term winners. Demand for robotics systems and surveillance, such as in warehouses, has the potential to rise. Additionally, surveillance technology with infra-red thermometers or AI, was widely used to help detect, monitor and track patients and quarantined individuals.

Oil refineries are seeing much slower demand, with some estimates putting the shortfall at 20%-30% of global oil consumption. On the supply side, large state-owned refineries have cut run rates by 10% to 13% while private entities have cut less.

Small, 'tea-pot' refineries have cut run rates by 40%-50%, the lowest level in the past five years. If the current situation continues, industry consolidation may accelerate, which may be positive for private integrated refineries with lower cash cost levels.

Looking regionally, there's further potential downside for refineries. Mainland China will likely see an inventory build-up, which may mean increased exports in 2Q20 and margin pressure for regional refineries. Furthermore, the recent global spike in cases will probably drive a further decrease in demand, thus forcing run rate cuts for regional refineries.

Sales and construction in China will take at least a month or two to ramp up. Developers are unlikely to launch projects until late-March and the slow return of migrant workers will weigh on project builds. .

An imminent liquidity crisis is unlikely, but smaller developers will continue to face difficulties – media are reporting 80 bankruptcies for small developers YTD, compared to 400+ in FY 2019.

Weak sentiment and tight financing will likely drive consolidation, with state-owned enterprises and larger developers likely to gain market share.

Retail landlords in general will be more negatively impacted. They need to assist tenants because of lost sales. Moreover, the shift of purchasing behavior from offline to online will quicken, potentially resulting in long term loss of business for retail landlords.

Number of bankruptcies

FY 2019: 400+
FY 2020 YTD: 80

Subscribe now

Perspectives matter. Tune in to our insights.

More insights

Singapore Retail Investors


This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2020 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.